

# Ji-Yan Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9520102/publications.pdf>

Version: 2024-02-01

81  
papers

1,726  
citations

361413

20  
h-index

315739

38  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2105  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. <i>Nature Medicine</i> , 2000, 6, 1160-1166.  | 30.7 | 224       |
| 2  | Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1597-1604.  | 4.2  | 135       |
| 3  | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 43-51.   | 7.0  | 125       |
| 4  | Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. <i>Blood</i> , 2003, 102, 1815-1823.  | 1.4  | 107       |
| 5  | Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.   | 3.5  | 75        |
| 6  | Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e702-e708.  | 3.7  | 70        |
| 7  | Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.   | 17.1 | 68        |
| 8  | Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.   | 3.9  | 62        |
| 9  | Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.  | 7.0  | 54        |
| 10 | Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.  | 4.8  | 54        |
| 11 | Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.  | 3.5  | 50        |
| 12 | The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. <i>Prostate</i> , 2015, 75, 1247-1254.   | 2.3  | 49        |
| 13 | Super-resolution observation of lysosomal dynamics with fluorescent gold nanoparticles. <i>Theranostics</i> , 2020, 10, 6072-6081.  | 10.0 | 43        |
| 14 | Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.  | 12.8 | 40        |
| 15 | The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells. <i>Tumor Biology</i> , 2016, 37, 8555-8566.  | 1.8  | 39        |
| 16 | Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. <i>Clinical Cancer Research</i> , 2022, 28, 489-497.                                     | 7.0  | 36        |
| 17 | A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4509-4509.  | 1.6  | 32        |
| 18 | The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. <i>Oncotarget</i> , 2017, 8, 55374-55383. | 1.8  | 30        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4520-4520.   | 1.6  | 23        |
| 20 | AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. <i>Prostate</i> , 2019, 79, 1553-1562.                                  | 2.3  | 22        |
| 21 | iRGD decorated liposomes: A novel actively penetrating topical ocular drug delivery strategy. <i>Nano Research</i> , 2020, 13, 3105-3109.   | 10.4 | 22        |
| 22 | Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.   | 3.8  | 20        |
| 23 | Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.   | 2.8  | 19        |
| 24 | Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma: A Pilot Study. <i>Cancer Investigation</i> , 2005, 23, 123-128.   | 1.3  | 17        |
| 25 | Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status. <i>BioMed Research International</i> , 2013, 2013, 1-7.  | 1.9  | 16        |
| 26 | Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2018, 54, 348-360.   | 3.3  | 16        |
| 27 | An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4584-4584. | 1.6  | 16        |
| 28 | Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2021, 81, 721-727.  | 2.3  | 15        |
| 29 | Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus. <i>Pathology and Oncology Research</i> , 2016, 22, 773-779.  | 1.9  | 14        |
| 30 | The Role of Neoantigens in Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 682325.   | 2.8  | 14        |
| 31 | Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small cell lung cancer patients treated with PD-1 inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 2914-2923.   | 1.9  | 13        |
| 32 | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. <i>International Journal of Ophthalmology</i> , 2022, 15, 646-656.  | 1.1  | 12        |
| 33 | S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 591-e165.   | 3.7  | 11        |
| 34 | Single-molecule quantification of 5-methylcytosine and 5-hydroxymethylcytosine in cancer genome. <i>View</i> , 2020, 1, e9.   | 5.3  | 11        |
| 35 | Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.  | 5.4  | 11        |
| 36 | Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 1681.   | 2.8  | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Phase I clinical trial of $^{111}\text{In}$ -labeled PSMA: A deuterated form of enzalutamide. <i>International Journal of Cancer</i> , 2021, 149, 1473-1482.  | 5.1 | 9         |
| 38 | Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2108-2118.                           | 1.0 | 9         |
| 39 | Epigenetic Quantification of DNA 5-Hydroxymethylcytosine Using DNA Hybridization-Based Single-Molecule Immunofluorescent Imaging. <i>Small Methods</i> , 2021, 5, e2100061.   | 8.6 | 8         |
| 40 | Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1559-1566. | 1.0 | 8         |
| 41 | Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2022, 23, 165.   | 1.8 | 8         |
| 42 | Clinical significance of serum CA125 in diffuse malignant mesothelioma. <i>SpringerPlus</i> , 2016, 5, 368.   | 1.2 | 7         |
| 43 | A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. <i>Gastric Cancer</i> , 2016, 19, 245-254.  | 5.3 | 7         |
| 44 | Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e135-e137.   | 1.9 | 6         |
| 45 | Comparative study of (Asp) <sup>7</sup> -CHOL-modified liposome prepared using pre-insertion and post-insertion methods for bone targeting <i>in vivo</i> . <i>Journal of Drug Targeting</i> , 2017, 25, 149-155.   | 4.4 | 6         |
| 46 | Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 365-373.   | 0.7 | 6         |
| 47 | Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4565-4565.  | 1.6 | 6         |
| 48 | First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. <i>Cancer Medicine</i> , 2021, 10, 3388-3402.  | 2.8 | 5         |
| 49 | Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study. <i>Oncotarget</i> , 2017, 8, 97890-97899.  | 1.8 | 5         |
| 50 | Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03. <i>Journal of Clinical Oncology</i> , 2020, 38, 5040-5040.   | 1.6 | 5         |
| 51 | Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110562.   | 1.3 | 5         |
| 52 | A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. <i>Medical Oncology</i> , 2015, 32, 247.   | 2.5 | 4         |
| 53 | 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. <i>Carcinogenesis</i> , 2018, 39, 493-502.  | 2.8 | 4         |
| 54 | Advanced Scrotal Extramammary Paget's Disease Treated With Apatinib: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e339-e342.   | 1.9 | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas. <i>Cancer Medicine</i> , 2021, 10, 5415-5428. | 2.8 | 4         |
| 56 | Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. <i>Oncotarget</i> , 2017, 8, 68270-68279.   | 1.8 | 4         |
| 57 | Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.  | 4.4 | 4         |
| 58 | Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570268.  | 2.8 | 3         |
| 59 | Bevacizumab Combined with Sâ€ and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326.  | 3.7 | 3         |
| 60 | Identifying tumor antigens and immunoâ€subtyping in colon adenocarcinoma to facilitate the development of <sc>mRNA</sc> vaccine. <i>Cancer Medicine</i> , 2022, , .  | 2.8 | 3         |
| 61 | Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. <i>Oncology Letters</i> , 2016, 11, 3501-3507.  | 1.8 | 2         |
| 62 | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 548867.   | 2.8 | 2         |
| 63 | A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype. <i>Oncogene</i> , 2020, 39, 6871-6878.   | 5.9 | 2         |
| 64 | Increased proportion of the squamous cell carcinoma component is associated with worse survival in resected gastric adenosquamous carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21980.  | 1.0 | 2         |
| 65 | Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4628-4628.                            | 1.6 | 2         |
| 66 | Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 727.  | 0.9 | 1         |
| 67 | Selected proliferation markers correlated with dynamics of growth in colorectal cancer. <i>European Journal of Cancer Prevention</i> , 2019, 28, 181-187.   | 1.3 | 1         |
| 68 | Expression and prognostic value of epithelialâ€mesenchymal transition and cancer stem cell markers in primary lesions and liver metastases of colorectal cancers. <i>Oncology Letters</i> , 2021, 22, 499.   | 1.8 | 1         |
| 69 | Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1-1.                          | 1.6 | 1         |
| 70 | Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study (POLARIS-03).. <i>Journal of Clinical Oncology</i> , 2020, 38, 504-504.  | 1.6 | 1         |
| 71 | Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report. <i>Asian Journal of Surgery</i> , 2022, , .  | 0.4 | 1         |
| 72 | Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Current Oncology</i> , 2022, 29, 267-282.                          | 2.2 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. <i>Future Oncology</i> , 0, , .  | 2.4 | 1         |
| 74 | Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e423-e425.  | 1.9 | 0         |
| 75 | Immunotherapy with Recombinant Xenogeneic Vascular Endothelial Growth Factor as a Vaccine Combined Low-Dose Adriamycin Induces Synergistic Antitumor Efficacy in EL4 Lymphoma Model.. <i>Blood</i> , 2005, 106, 4811-4811.                                 | 1.4 | 0         |
| 76 | Bevacizumab plus S-1 and raltitrexed for refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16024-e16024.  | 1.6 | 0         |
| 77 | Recombinant humanized Anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma (POLARIS-03 study): Two-year survival update and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 508-508.            | 1.6 | 0         |
| 78 | Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. <i>Immunotherapy</i> , 2022, 14, 309-320.   | 2.0 | 0         |
| 79 | Efficacy and safety of raltitrexed plus S-1 <i>versus</i> regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982. | 3.2 | 0         |
| 80 | Epidemiology, Treatment, and Outcome of Pancreatic Squamous Cell Carcinoma and Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis Based on SEER-Database. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211065.     | 1.9 | 0         |
| 81 | Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4566-4566.                | 1.6 | 0         |